Early Versus Late Administration of Long-Acting Insulin in Adult Diabetic Ketoacidosis

被引:0
|
作者
Do, Michael M. [1 ]
Fleury, Jacklyn A. [2 ]
Morgan, Grant P. [1 ]
Zimmerman, Lisa Hall [1 ]
Hanni, Claudia M. [1 ]
Sulaiman, Hiba [1 ]
Lutz, Mark F. [1 ]
机构
[1] Corewell Hlth William Beaumont Univ Hosp, Dept Pharm Serv, 3601 West 13 Mile Rd, Royal Oak, MI 48073 USA
[2] Wayne State Univ, Eugene Applebaum Coll Pharm & Hlth Sci, Detroit, MI USA
关键词
diabetic ketoacidosis; insulin; hyperglycemia; GLARGINE; MANAGEMENT;
D O I
10.1177/10600280241278371
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Evidence is inconclusive if early administration of subcutaneous (SQ) long-acting insulin (LAI) in management of diabetic ketoacidosis (DKA) improves outcomes. Objective: This study compares early versus late administration of SQ LAI in time to DKA resolution. Methods: This single-center, retrospective study included patients with DKA who received >= 12 hours of continuous intravenous insulin (CIVI) with LAI overlap. Patients were compared based on LAI administration time to CIVI initiation: Early (<12 hours) versus Late (>= 12 hours). The DKA resolution is defined as blood glucose < 200 mg/dL and 2 of the following: anion gap < 12 mEq/L, pH > 7.35, or serum carbon dioxide >15 mEq/L. Outcomes included time to DKA resolution, length of stay (LOS), CIVI duration, and adverse events. Results: A total of 27 patients were included in each group. Baseline characteristics were similar between both groups. There was no difference in time to DKA resolution, Early = 17.6 (13.9-26.8) hours versus Late = 19.2 (17.1-32.1) hours, P = 0.16. The Early group had shorter CIVI duration (Early = 19.5 +/- 10.3 hours vs Late = 25.6 +/- 8.4 hours, P = 0.02) and received less intravenous (IV) fluids in the first 36 hours (Early = 4.04 +/- 2.12 L vs Late = 5.85 +/- 2.24 L, P = 0.004). No differences were identified with adverse events, including hypoglycemia, or LOS. Conclusion and Relevance: Administration of SQ LAI < 12 hours did not decrease time to DKA resolution or LOS. Patients in the Early group had received a lower dose of LAI, shorter duration of CIVI infusion, and required less IV fluids within 36 hours of admission. This study supports the need for further research to determine the potential benefits of administering SQ insulin early in managing DKA.
引用
收藏
页数:5
相关论文
共 50 条
  • [41] Insulin detemir (Levemir), a new long-acting insulin
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2006, 48 (1238): : 54 - 55
  • [42] Insulin glargine: A new long-acting insulin product
    Reinhart, L
    Panning, CA
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2002, 59 (07) : 643 - 649
  • [43] Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis
    Andrade-Castellanos, Carlos A.
    Enrique Colunga-Lozano, Luis
    Delgado-Figueroa, Netzahualpilli
    Gonzalez-Padilla, Daniel A.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (01):
  • [44] Subcutaneous Rapid-acting Insulin Analogs for Diabetic Ketoacidosis
    Chow, Lillian
    Valesky, Walter
    ACADEMIC EMERGENCY MEDICINE, 2021, 28 (06) : 700 - 702
  • [45] EFFECT OF BOLUS INSULIN ADMINISTRATION ON DIABETIC KETOACIDOSIS MANAGEMENT
    Dills, Hannah
    Tran, Richard
    Patka, John
    CRITICAL CARE MEDICINE, 2019, 47
  • [46] The effect of early or late initiation of long-acting antipsychotics on the caregiver burden in schizophrenia
    Cirakman, Dilara
    Karslioglu, Ersin Hatice
    Bal, Nese Burcu
    Caykoylu, Ali
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2024, 39 (05) : 313 - 322
  • [47] EARLY SIGNALING EVENTS AND MITOGENICITY OF THE LONG-ACTING INSULIN NN-304
    LUNDEMOSE, AG
    HANSEN, BF
    DREJER, K
    DIABETOLOGIA, 1995, 38 : A192 - A192
  • [48] Association of Cardiovascular Outcomes and Mortality With Sustained Long-Acting Insulin Only vs Long-Acting Plus Short-Acting Insulin Treatment
    Schroeder, Emily B.
    Neugebauer, Romain
    Reynolds, Kristi
    Schmittdiel, Julie A.
    Loes, Linda
    Dyer, Wendy
    Pimentel, Noel
    Desai, Jay R.
    Vazquez-Benitez, Gabriela
    Ho, P. Michael
    Anderson, Jeffrey P.
    O'Connor, Patrick J.
    JAMA NETWORK OPEN, 2021, 4 (09)
  • [49] NEWER LONG-ACTING BASAL INSULIN PREPARATIONS
    Blonde, Lawrence
    ENDOCRINE PRACTICE, 2017, 23 : 13 - 17
  • [50] An update on the long-acting insulin analogue glargine
    Thisted, Henriette
    Johnsen, Soren Paaske
    Rungby, Jorgen
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2006, 99 (01) : 1 - 11